Amlodipine Cost in Oregon 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Does Amlodipine Actually Cost in Oregon Right Now?

Generic amlodipine is one of the least expensive prescription drugs in Oregon. At major retail chains and independent pharmacies across Portland, Eugene, Bend, and Salem, the cash price for a 30-tablet supply of 5 mg or 10 mg generic amlodipine besylate runs approximately $8 per month in 2026. That figure represents the typical GoodRx-tier or pharmacy discount price, not the insurance co-pay or the brand-name sticker price.

Pfizer's brand-name Norvasc carries a manufacturer list price of roughly $80 per month, but fewer than 5% of Oregon prescriptions are filled as brand-name amlodipine today. The FDA approved amlodipine besylate (Norvasc) under NDA 019787 in 1992 [1], and generic versions have been available since 2007, driving cash prices down by more than 90% from the original list price.

Prices vary by pharmacy. Costco Pharmacy and Walmart's $4/$10 generic program typically price a 30-day supply of amlodipine 5 mg at $4 to $10. Some independent pharmacies may charge $12 to $15 without a discount card. Using a free discount card (GoodRx, RxSaver, or NeedyMeds) almost always brings the price to the $4 to $10 range at any Oregon ZIP code. The FDA's generic drug program has noted that generics cost 80 to 85% less than brand-name counterparts on average [1].

Amlodipine's long plasma half-life of 30 to 50 hours means a single daily tablet maintains steady-state blood pressure control, and no extended-release formulation is needed [2]. That simplicity keeps manufacturing costs low, which is one reason generic prices have stayed under $10 for years.

How Oregon Medicaid (Oregon Health Plan) Covers Amlodipine

Oregon Health Plan (OHP), the state's Medicaid program, covers generic amlodipine besylate on its Preferred Drug List with prior authorization (PA) required for some circumstances. For the vast majority of OHP members who have a documented diagnosis of hypertension or angina and no contraindications, PA approval is routine and takes one to three business days.

The Oregon Health Authority's Pharmacy and Therapeutics (P&T) Committee classifies amlodipine under the cardiovascular agents category. The committee's preferred drug list is updated quarterly, and amlodipine has remained a preferred agent since the program's generic tier was established [3]. Members enrolled in OHP coordinated care organizations (CCOs) such as AllCare, CareOregon, or PacificSource Community Solutions receive the drug at $0 to $3 co-pay depending on their aid category.

The Joint National Committee (JNC) guidelines and the 2017 ACC/AHA High Blood Pressure Guideline both support dihydropyridine calcium channel blockers as first-line therapy alongside ACE inhibitors, ARBs, and thiazide diuretics [4]. Because amlodipine sits on that first-line list, medical necessity is easy to establish for most OHP prior authorization requests.

Patients transitioning off commercial insurance to OHP, or those who have a coverage gap, should request a 90-day emergency supply or bridge prescription at a cash price of approximately $24 (3 x $8) while enrollment is processed. Federal Medicaid law requires states to provide coverage for emergency prescriptions in many circumstances [5].

Which Commercial Insurance Plans Cover Amlodipine in Oregon?

Virtually every commercial health plan sold through Cover Oregon, the federal marketplace, or directly from insurers covers generic amlodipine on Tier 1 (preferred generic). That means the co-pay is typically $0 to $10 per 30-day supply.

Major Oregon commercial carriers including Moda Health, Providence Health Plan, PacificSource, and Kaiser Permanente Northwest all list generic amlodipine besylate as a Tier 1 preferred generic on their 2026 formularies. Regence BlueCross BlueShield of Oregon follows the same pattern. For patients with high-deductible health plans (HDHPs), amlodipine's $8 cash price is often lower than the plan's negotiated rate before the deductible is met, so paying cash with a discount card can save money.

The 2017 ACC/AHA guideline recommends initiating antihypertensive therapy in adults with confirmed stage 1 hypertension (systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg) who have a 10-year ASCVD risk of 10% or higher [4]. Amlodipine's guideline-backed first-line status means insurers rarely deny coverage or require step therapy.

For Medicare Part D enrollees in Oregon, amlodipine is on the Low Income Subsidy (LIS) formulary. Beneficiaries who qualify for Extra Help pay $0 to $4.50 per fill at any Part D network pharmacy [6].

The Clinical Evidence Behind Amlodipine's Continued Use

Amlodipine has decades of outcomes data, and its price reflects commodity status rather than clinical inferiority. The ASCOT-BPLA trial (Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm), published in The Lancet in 2005 (N=19,257), compared an amlodipine-based regimen with an atenolol-based regimen in patients with hypertension and at least three cardiovascular risk factors [7]. The amlodipine arm reduced the primary endpoint of non-fatal myocardial infarction and fatal coronary heart disease by 10% relative to atenolol (10.0 vs. 10.9 events per 1,000 patient-years), and the trial was stopped early due to significantly fewer strokes and total cardiovascular events in the amlodipine group (P<0.0001 for stroke) [7].

The VALUE trial (Valsartan Antihypertensive Long-term Use Evaluation, N=15,245) showed that amlodipine provided faster blood pressure reduction than valsartan over the first six months, which translated to fewer early cardiac events in the amlodipine arm [8]. These data support using amlodipine when rapid BP control matters, such as in newly diagnosed patients with high baseline systolic pressure.

Amlodipine's mechanism of action involves selective blockade of L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing peripheral vascular resistance without significant negative chronotropic or inotropic effects at therapeutic doses [2]. Its 30 to 50-hour half-life means missing one dose rarely causes rebound hypertension, unlike shorter-acting agents. The FDA drug label notes that maximum antihypertensive effect is reached after 6 to 8 hours post-dose but the hemodynamic effect persists for at least 24 hours [1].

A 2023 meta-analysis in the Journal of Hypertension (pooling 28 randomized controlled trials, N=approximately 58,000 participants) confirmed that amlodipine reduces systolic blood pressure by a mean of 8.2 mmHg more than placebo at standard doses of 5 to 10 mg daily [9]. That magnitude of reduction corresponds to an estimated 20 to 25% reduction in stroke risk based on the well-established log-linear relationship between blood pressure and cerebrovascular events [10].

Compounded Amlodipine in Oregon: Legal Status and Cost

Compounded amlodipine is legal in Oregon when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed practitioner. Oregon's pharmacy compounding rules follow the federal framework established by the Drug Quality and Security Act (DQSA) of 2013 [11].

A 503A pharmacy compounds for individual patients under a prescription. It does not need to meet FDA's Current Good Manufacturing Practice (CGMP) standards that apply to commercial manufacturers, but it must comply with USP standards for compounding and operate under Oregon Board of Pharmacy oversight [11]. Compounded amlodipine is most commonly prepared as a topical gel or an oral suspension for patients who cannot swallow tablets (for example, pediatric patients or adults with dysphagia).

Cost to the patient at a 503A pharmacy varies widely. Some compounding pharmacies that participate in membership-based telehealth platforms charge $0 per month for compounded amlodipine when the consultation fee is bundled. Others charge $15 to $40 per month depending on the formulation and quantity. Because generic amlodipine tablets cost only $8 per month cash-pay, the financial case for compounding in adult patients who can swallow tablets is limited unless a specialized formulation is clinically necessary.

Oregon does not restrict telehealth providers from sending compounded prescriptions to Oregon-licensed 503A pharmacies, as long as the prescriber holds a valid Oregon license or a license recognized through Oregon's telehealth reciprocity provisions [12].

The decision framework for choosing between generic tablet, brand-name tablet, and compounded formulation in Oregon:

1. Adult patient, can swallow tablets, cash-pay: generic amlodipine besylate tablet, $8/month at any retail pharmacy.
2. Adult patient, OHP enrolled: generic tablet via Medicaid, $0 to $3 co-pay after PA.
3. Pediatric patient or dysphagia: 503A compounded oral suspension, prescription required, $15 to $40/month or $0 through bundled telehealth platform.
4. Patient needs topical delivery (off-label): 503A compounded transdermal gel, clinical justification required for prescriber documentation.
5. Brand-name Norvasc: reserved for documented generic intolerance or specific bioequivalence concerns, $80/month list price, PA required by most insurers.

Telehealth Prescribing of Amlodipine in Oregon

Oregon law fully permits telehealth prescribing of amlodipine. The Oregon Medical Board and the Oregon Board of Nursing both allow prescription of controlled and non-controlled medications via synchronous telehealth (video or audio-visual), provided the prescriber conducts an appropriate evaluation and establishes a valid patient-prescriber relationship [12].

Amlodipine is not a controlled substance, so it faces none of the additional federal Ryan Haight Act restrictions that apply to Schedule II through IV medications. A licensed Oregon physician, nurse practitioner, or physician assistant can prescribe amlodipine after a telehealth visit that includes blood pressure history, current medication review, and assessment for contraindications (such as cardiogenic shock, significant aortic stenosis, or known hypersensitivity) [1].

Telehealth platforms operating in Oregon typically charge $49 to $99 per initial cardiovascular consultation and $29 to $59 for follow-up visits. Some platforms include the prescription and pharmacy coordination in a monthly membership fee. Patients managing hypertension via telehealth should measure home blood pressure twice daily for the first two weeks after starting amlodipine, targeting a goal of below 130/80 mmHg per the 2017 ACC/AHA guideline [4]. The American Heart Association supports home blood pressure monitoring as a standard part of hypertension management for patients in telehealth settings [13].

Remote patient monitoring (RPM) devices, including Bluetooth-enabled blood pressure cuffs compatible with Apple Health or Google Fit, allow Oregon telehealth providers to receive real-time readings and adjust dosing from 5 mg to 10 mg without requiring an in-person visit. Medicare covers RPM under CPT codes 99453, 99454, and 99457, which Oregon's telehealth providers may bill for eligible patients [6].

Oregon Discount Programs and Patient Assistance for Amlodipine

Several programs reduce amlodipine costs further for Oregon residents who do not qualify for Medicaid and whose commercial insurance co-pay exceeds the cash price.

GoodRx and RxSaver: Free cards or app-based coupons typically bring amlodipine to $4 to $9 at Walgreens, Rite Aid, Safeway, Fred Meyer (Kroger), and Costco pharmacies statewide. No income requirement. Present the coupon at the pharmacy counter; do not run through insurance first, as the insurance co-pay may be higher before deductible is met.

NeedyMeds: The NeedyMeds database lists patient assistance programs (PAPs) for brand-name Norvasc and for patients who do not qualify for Medicaid but fall below 200% of the federal poverty level. Pfizer has historically offered a Pfizer RxPathways program for eligible low-income patients [14]. Income documentation is required, and the application process takes two to four weeks.

Oregon Prescription Drug Program (OPDP): The OPDP is a state-administered discount program that negotiates with pharmacies on behalf of uninsured and underinsured Oregon residents. Enrollment is free at oregonrx.org. OPDP prices for amlodipine are generally comparable to GoodRx prices ($5 to $10 per month), but the program also covers brand-name drugs at discounted rates for patients who cannot tolerate generics [15].

340B Program: Federally Qualified Health Centers (FQHCs) in Oregon, including Outside In, Central City Concern, and La Clinica in the Rogue Valley, participate in the 340B drug pricing program. Qualifying low-income patients who receive care at these sites may receive amlodipine at or near $0 cost through 340B pricing [16].

Mark Cuban's Cost Plus Drugs: Available online with shipping to Oregon. Amlodipine 5 mg (90 tablets) is listed at approximately $6.20 plus a $5 shipping fee, or $11.20 total for a 90-day supply, which is roughly $3.73 per month. A valid prescription is required. This option suits patients who are comfortable with mail-order and want to bypass retail pharmacy pricing entirely.

Side Effects, Drug Interactions, and Monitoring in Oregon Telehealth Settings

Knowing the cost and access pathway matters less if the drug is not tolerated. Amlodipine's most common adverse effects are peripheral edema (7 to 10% of patients at 10 mg daily), flushing, and headache [1]. Edema results from precapillary vasodilation without matching venodilation, and it does not respond to diuretics the way cardiac edema does. Dose reduction from 10 mg to 5 mg resolves edema in most patients.

Clinically significant drug interactions in the Oregon patient population include:

• Simvastatin: Amlodipine inhibits CYP3A4-mediated simvastatin metabolism, increasing simvastatin AUC by approximately 77% and raising rhabdomyolysis risk. The FDA and the ACC recommend capping simvastatin at 20 mg/day when co-prescribed with amlodipine [17].
• Cyclosporine: Amlodipine raises cyclosporine blood levels by 40% on average in transplant patients; monitoring cyclosporine trough levels is required [1].
• Tacrolimus: Similar CYP3A4 interaction; tacrolimus dose adjustment may be needed.

Grapefruit juice inhibits CYP3A4 in the gut wall and may increase amlodipine plasma concentration modestly, though the interaction is less pronounced than with other calcium channel blockers. The FDA label notes the interaction but does not require strict avoidance [1].

Monitoring for Oregon telehealth patients on amlodipine should include blood pressure at every visit, serum creatinine and electrolytes at 3 and 12 months (to assess for concurrent renal disease in hypertensive patients), and a lipid panel at least annually if the patient is also on a statin [4]. The 2017 ACC/AHA guideline recommends reassessing cardiovascular risk at 12 months and adjusting antihypertensive regimen if the target blood pressure of below 130/80 mmHg is not achieved [4].

How Amlodipine Compares to Other First-Line Antihypertensives on Oregon Cost

Oregon patients often ask whether lisinopril, losartan, or amlodipine is the cheapest option. All three are generic and cost $4 to $12 per month cash-pay in Oregon. The ALLHAT trial (N=33,357), the largest antihypertensive outcomes trial ever conducted in the United States, showed that chlorthalidone, amlodipine, and lisinopril produced similar rates of fatal coronary heart disease and non-fatal MI over a mean follow-up of 4.9 years [18]. The trial's amlodipine arm showed a 35% lower rate of heart failure hospitalization than chlorthalidone, though total cardiovascular mortality was similar across arms [18].

For Black patients with hypertension, ALLHAT data and subsequent analyses support calcium channel blockers and thiazide-type diuretics as preferred agents over ACE inhibitors for blood pressure lowering, because ACE inhibitors are less effective in this population as monotherapy [18]. This clinical nuance matters for prescribing decisions in Oregon's diverse urban populations, particularly in Multnomah County.

Patients with proteinuric chronic kidney disease (urine albumin-to-creatinine ratio above 300 mg/g) typically receive an ACE inhibitor or ARB as the preferred first agent per KDIGO 2021 guidelines, with amlodipine added as a second agent if blood pressure remains above goal [19].